Avandia Tops List for Safety Concerns

Avandia, GlaxoSmithKline’s diabetes drug, has topped the list of most reported adverse events for the third quarter of 2009. The report was published by The Institute for Safe Medication Practices. Avandia has been plagued by adverse events such as an increased risk of heart attacks since 2007 when Dr. Nissen of the Cleveland Clinic first linked the drug to cardiac problems.
GlaxoSmithKline received more bad news today about Avandia. UBS, one of the world’s largest financial firms forecast a potential $6 billion loss as a result of Avandia lawsuits in the United States. The financial firm noted that there are already more than 13,000 Avandia lawsuits with more expected as public awareness of Avandia’s safety concerns grow.
The first Avandia federal bellwether trial is scheduled to begin in Pennsylvania June 1. Last week a US Senate report was highly critical of GlaxoSmithKline for understating Avandia’s safety risks as well as its failure to report drug data to the FDA. There are also allegations that company officials coerced experts to downplay the Avandia risks.